Healthy
Conditions
Brief summary
An Open-Label, Randomized, 2-sequence, 2-period, Fasted Condition, Single-dose, Per Oral, Cross-over Study to Evaluate the Bioequivalence of Dong-a Bepotastine Besilate Tab (Bepotastine Besilate 10mg) and Twolion Tab (Bepotastine Besilate 10mg) in Healthy Volunteers
Detailed description
1. Study design: An open-Label, randomized, 2-sequence, 2-period, fasted condition, single-dose, per oral, cross-over study 2. Administration method: The subject should maintain a minimum of 10 hours of empty stomach before administration, and give an oral dose of 1 tablets (Bepotastine Besilate 10 mg) with 150 mL of water at around 8 a.m. on the day of the test at room temperature. The test subject should not chew the drug or break it, but should swallow in whole with water. The difference in administration time between the test subjects is about one minute apart, considering the collection time. 3. Wash out period: 7 days 4. Blood collection time: Before the administration, 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 3, 4, 6, 8, 12 hr after the administration (total 13 times) 5. Analysis: Measurement of the concentration of an unchangeable substance of Bepotastine in plasma
Interventions
DRUGFisrt period TWLO_C
First Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)
DRUGFisrt period TWLO
First Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)
OTHERWashout period
7 days
DRUGSecond period TWLO_C
Second Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)
DRUGSecond period TWLO
Second Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)
Sponsors
Dong-A ST Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
single-dose, 2-sequence
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. A person who aged 19 or older at the time of screening 2. No congenital or chronic diseases or pathological symptoms on screening 3. A person who is judged to be suitable for the study by the investigator based on the clinical laboratory examination 4. BMI of 18 to 30 (BMI calculation: kg/m2) 5. No history of gastrointestinal resection that may affect the absorption of drugs 6. No medical history of mental illness within five years prior to screening 7. A person who has fully understood the contents of the consent form for the study and signed the consent form voluntarily and recorded the date of signature 8. A person who is willing and able to follow all scheduled hospitalization and outpatient visits, medications, clinical laboratory examination and the terms of compliance 9. Female patients who were confirmed to be not pregnant at medical examination
Exclusion criteria
1. A person who has taken a drug that significantly induces (e.g., barbital) or inhibits the drug metabolic enzyme within 30 days prior to screening 2. A person who uses drugs that can affect the study within 10 days before screening 3. A person who is considered unsuitable to participate in the study by the investigator 4. A person who has participated in other clinical trials within three months prior to the first administration of the IP 5. A person who has had whole blood transfusion within 2 months or the apheresis within 2 weeks before screening 6. A person who is hypersensitive to venipuncture 7. A person with a history of regular alcohol intake within six months prior to screening: * Women: More than 14 cups/week * Men: More than 21 glasses/week (1 shot: 50 ml of soju, 30 ml of spirits, 250 ml of beer) 8. Hypersensitive to any of the IP components 9. Blood AST (GOT) or ALT (GPT) levels exceed the upper reference range limit by 2 times or γ-GTP levels exceed the upper reference range limit by 1.5 times 10. Lactating women 11. A person who does not agree to exclude the possibility of pregnancy using the contraception from the date of the first administration of the IP until the 7th day after the last administration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area Under the plasma Concetration versus time curve(AUClast) of Bepotastine Besilate | Before administration ~ 12 hours |
| Peak Plasma Concentration(Cmax) of Bepotastine Besilate | Before administration ~ 12 hours |
Countries
South Korea
Outcome results
None listed